Evidence map›Paper›PMID 31212833›Full record

Trial reportCells2019

Contribution of the Gut Microbiota in P28GST-Mediated Anti-Inflammatory Effects: Experimental and Clinical Insights.

Benoît Foligné, Coline Plé, Marie Titécat, Arnaud Dendooven, Aurélien Pagny, Catherine Daniel, Elisabeth Singer, Muriel Pottier, Benjamin Bertin, Christel Neut and 5 more

Registry-linked trialOpen access · goldAbstract readClinical Trial, Phase II
In one paragraph

Trial report in Cells, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02281916 (Safety Study of P28GST Treatment in Crohn's Disease Patients, a Multicenter Phase 2 Clinical Trial), which is not on this map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02281916 phase2completednot on this map

Safety Study of P28GST Treatment in Crohn's Disease Patients, a Multicenter Phase 2 Clinical Trial

TypeinterventionalSponsorUniversity Hospital, LilleRan2014 to 2018Enrolled10ConditionsCrohn's IleocolitisArmsP28GST
3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.

  1. Guideline
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Landscape of new drugs and targets in inflammatory bowel disease.United European gastroenterology journal · 2022
    Review
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 1 country.

Benoît FolignéUniv. Lille, Inserm, CHU Lille, U995 - LIRIC - Lille Inflammation Research International Center, F-59000 Lille, France. benoit.foligne@univ-lille.fr.
Coline PléUniv. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019 - UMR 8204 - CIIL - Center for Infection and Immunity of Lille, F-59000 Lille, France. coline.ple@ibl.cnrs.fr.
Marie TitécatUniv. Lille, Inserm, CHU Lille, U995 - LIRIC - Lille Inflammation Research International Center, F-59000 Lille, France. marie.titecat@chru-lille.fr.
Arnaud DendoovenUniv. Lille, Inserm, CHU Lille, U995 - LIRIC - Lille Inflammation Research International Center, F-59000 Lille, France. arnaud.dendooven@gmail.com.
Aurélien PagnyUniv. Lille, Inserm, CHU Lille, U995 - LIRIC - Lille Inflammation Research International Center, F-59000 Lille, France. pagny.aurelien@gmail.com.
Catherine DanielUniv. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019 - UMR 8204 - CIIL - Center for Infection and Immunity of Lille, F-59000 Lille, France. catherine.daniel@ibl.cnrs.fr.
Elisabeth SingerUniv. Lille, Inserm, CHU Lille, U995 - LIRIC - Lille Inflammation Research International Center, F-59000 Lille, France. elisabeth.singer@univ-lille.fr.
Muriel PottierUniv. Lille, Inserm, CHU Lille, U995 - LIRIC - Lille Inflammation Research International Center, F-59000 Lille, France. muriel.pottier@univ-lille.fr.
Benjamin BertinUniv. Lille, Inserm, CHU Lille, U995 - LIRIC - Lille Inflammation Research International Center, F-59000 Lille, France. benjamin.bertin@univ-lille.fr.
Christel NeutUniv. Lille, Inserm, CHU Lille, U995 - LIRIC - Lille Inflammation Research International Center, F-59000 Lille, France. christelneut@nordnet.fr.
Dominique DeplanqueUniv. Lille, Inserm, CHU Lille, CIC 1403, Centre d'investigation clinique, F-59000 Lille, France. Dominique.DEPLANQUE@CHRU-LILLE.FR.
Laurent DubuquoyUniv. Lille, Inserm, CHU Lille, U995 - LIRIC - Lille Inflammation Research International Center, F-59000 Lille, France. laurent.dubuquoy@inserm.fr.
Pierre DesreumauxUniv. Lille, Inserm, CHU Lille, U995 - LIRIC - Lille Inflammation Research International Center, F-59000 Lille, France. pdesreumaux@hotmail.com.
Monique CapronUniv. Lille, Inserm, CHU Lille, U995 - LIRIC - Lille Inflammation Research International Center, F-59000 Lille, France. monique.capron@univ-lille.fr.
Annie StandaertUniv. Lille, Inserm, CHU Lille, U995 - LIRIC - Lille Inflammation Research International Center, F-59000 Lille, France. annie.standaert@univ-lille.fr.
Inserm · FRCentre National de la Recherche Scientifique · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

An original immuno-regulatory strategy against inflammatory bowel diseases based on the use of 28 kDa glutathione S-transferase (P28GST), a unique schistosome protein, was recently proposed. Improvement of intestinal inflammation occurs through restoration of the immunological balance between pro-inflammatory T-helper 1 (Th1) responses and both T-helper 2 (Th2) and regulatory responses. However, detailed mechanisms explaining how P28GST prevents colitis and promotes gut homeostasis remain unknown. Considering the complex interplay between the adaptive and innate immune system and the intestinal microbiota, we raised the question of the possible role of the microbial ecosystem in the anti-inflammatory effects mediated by the helminth-derived P28GST protein. We first analyzed, by 16S rRNA sequencing, the bacterial profiles of mice fecal microbiota at several time points of the P28GST-immunomodulation period prior to trinitrobenzene sulfonic acid (TNBS)-colitis. The influence of gut microbiota in the P28GST-mediated anti-inflammatory effects was then assessed by fecal microbiota transplantation experiments from P28GST-immunized mice to either conventional or microbiota depleted naïve recipient mice. Finally, the experimental data were supplemented by the temporal fecal microbiota compositions of P28GST-treated Crohn's disease patients from a pilot clinical study (NCT02281916). The P28GST administration slightly modulated the diversity and composition of mouse fecal microbiota while it significantly reduced experimental colitis in mice. Fecal microbiota transplantation experiments failed to restore the P28GST-induced anti-inflammatory effects. In Crohn's disease patients, P28GST also induced slight changes in their overall fecal bacterial composition. Collectively, these results provide key elements in both the anti-inflammatory mechanisms and the safe therapeutic use of immunomodulation with such promising helminth-derived molecules.

Indexed as

Gastrointestinal MicrobiomeAnimalsAnti-Bacterial AgentsAnti-Inflammatory AgentsColitisCrohn DiseaseFecal Microbiota TransplantationFecesFemaleGlutathione TransferaseHumansImmunizationImmunomodulationMice, Inbred BALB CPhenotypeTrinitrobenzenesulfonic AcidAnti-Bacterial AgentsAnti-Inflammatory AgentsGlutathione TransferaseTrinitrobenzenesulfonic Acidfecal microbiotafecal transplantationhelminth proteinhumansimmunizationinflammatory bowel diseasesmice

Identifiers

PMID31212833
PMCPMC6627314
OpenAlexW2950837356

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.